1.
Kathy Archibald, Katya Tsaioun, J. Gerry Kenna, Pandora Pound. Better science for safer medicines: the human imperative. Journal of the Royal Society of Medicine. 2018;111(12):433-438. doi:10.1177/0141076818812783
Drug Discovery
1.
Dorothée Diogo, Chao Tian, Christopher S. Franklin, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nature Communications. 2018;9(1):4285. doi:10.1038/s41467-018-06540-3
1.
William G. Kaelin. Common pitfalls in preclinical cancer target validation. Nature Reviews. Cancer. 2017;17(7):425-440. doi:10.1038/nrc.2017.32
1.
Monya Baker. Reproducibility crisis: Blame it on the antibodies. Nature. 2015;521(7552):274-276. doi:10.1038/521274a
1.
Eric W. Esch, Anthony Bahinski, Dongeun Huh. Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery. 2015;14(4):248-260. doi:10.1038/nrd4539
1.
Matthew M. Davis, Amy T. Butchart, John R. C. Wheeler, Margaret S. Coleman, Dianne C. Singer, Gary L. Freed. Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine. 2011;29(51):9414-9416. doi:10.1016/j.vaccine.2011.09.128
1.
Kerry Dwan, Carrol Gamble, Paula R. Williamson, Jamie J. Kirkham. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias — An Updated Review. PLOS ONE. 8(7):e66844. doi:10.1371/journal.pone.0066844